<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34321612</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-7254</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta pharmacologica Sinica</Title><ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation></Journal><ArticleTitle>Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses.</ArticleTitle><Pagination><StartPage>977</StartPage><EndPage>991</EndPage><MedlinePgn>977-991</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41401-021-00733-1</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is the major pathogens of human hand, foot, and mouth disease (HFMD). EV71 efficiently escapes innate immunity responses of the host to cause infection. At present, no effective antiviral drugs for EV71 are available. Anemoside B4 (B4) is a natural saponin isolated from the roots of Pulsatilla chinensis (Bunge) Regel. P. chinensis extracts that shows a wide variety of biological activities. In this study, we investigated the antiviral activities of B4 against EV71 both in cell culture and in suckling mice. We showed that B4 (12.5-200&#x2009;&#x3bc;M) dose dependently increased the viability of EV71-infected RD cells with an IC<sub>50</sub> value of 24.95&#x2009;&#xb1;&#x2009;0.05&#x2009;&#x3bc;M against EV71. The antiviral activity of B4 was associated with enhanced interferon (IFN)-&#x3b2; response, since knockdown of IFN-&#x3b2; abolished its antiviral activity. We also confirmed that the enhanced IFN response was mediated via activation of retinoic acid-inducible gene I (RIG-I) like receptors (RLRs) pathway, and it was executed by upregulation of 14-3-3 protein, which disrupted the interaction between yes-associated protein (YAP) and interferon regulatory factor 3 (IRF3). By using amino acids in cell culture (SILAC)-based proteomics profiling, we identified the Hippo pathway as the top-ranking functional cluster in B4-treated EV71-infected cells. In vivo experiments were conducted in suckling mice (2-day-old) infected with EV71 and subsequently B4 (200&#x2009;mg&#x2009;&#xb7;&#x2009;kg<sup>-1</sup>&#x2009;&#xb7;&#x2009;d<sup>-1</sup>, i.p.) was administered&#xa0;for 16 days. We showed that B4 administration effectively suppressed EV71 replication and improved muscle inflammation and limb activity. Meanwhile, B4 administration regulated the expressions of HFMD biomarkers IL-10 and IFN-&#x3b3;, attenuating complications of EV71 infection. Collectively, our results suggest that B4 could enhance the antiviral effect of IFN-&#x3b2; by orchestrating Hippo and RLRs pathway, and B4 would be a potential lead compound for developing an anti-EV71 drug.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to CPS and SIMM.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Nai-Xin</ForeName><Initials>NX</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Qing-Hua</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Er</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guo-Qiang</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Han-Dong</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Institute of Aging Research, School of Medicine, Hangzhou Normal University, Hangzhou, 310036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiong-Ming</ForeName><Initials>QM</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China. xuqiongming@suda.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. xuqiongming@suda.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shi-Lin</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Soochow University, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Pharmacol Sin</MedlineTA><NlmUniqueID>100956087</NlmUniqueID><ISSNLinking>1671-4083</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012503">Saponins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000620474">anemoside B4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012503" MajorTopicYN="Y">Saponins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">14-3-3 protein</Keyword><Keyword MajorTopicYN="N">Hippo pathway</Keyword><Keyword MajorTopicYN="N">anemoside B4</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">human hand, foot, and mouth disease</Keyword><Keyword MajorTopicYN="N">type I IFN</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34321612</ArticleId><ArticleId IdType="pmc">PMC8976028</ArticleId><ArticleId IdType="doi">10.1038/s41401-021-00733-1</ArticleId><ArticleId IdType="pii">10.1038/s41401-021-00733-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang ZC, Kou ZQ, Bai YJ, Cong X, Wang LH, Li C, et al. Epidemiological research on hand, foot, and mouth disease in mainland China. Viruses. 2015;7:6400&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690870</ArticleId><ArticleId IdType="pubmed">26690202</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih C, Liao CC, Chang YS, Wu SY, Chang CS, Liou AT. Immunocompetent and immunodeficient mouse models for enterovirus 71 pathogenesis and therapy. Viruses. 2018;10:674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6316343</ArticleId><ArticleId IdType="pubmed">30487421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) Expert Rev Vaccines. 2016;15:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-&#x3ba;B and IRF 3. Cell. 2005;122:669&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125763</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-&#x3b2; signaling. Mol Cell. 2005;19:727&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6:981&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16177806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YK, Gack MU. RIG-I-like receptor regulation in virus infection and immunity. Curr Opin Virol. 2015;12:7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076476</ArticleId><ArticleId IdType="pubmed">25644461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Xi XY, Lei XB, Zhang XY, Cui S, Wang JW, et al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog. 2013;9:e1003231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605153</ArticleId><ArticleId IdType="pubmed">23555247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake PS, Hsu AC, Wark PA. Innate immunity and immune evasion by enterovirus 71. Viruses. 2015;7:6613&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Wolf N, Lavelle EC. Hippo interferes with antiviral defences. Nat Cell Biol. 2017;19:267&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28361938</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Meng F, Chen S, Plouffe SW, Wu S, Liu S, et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat Cell Biol. 2017;19:362&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398908</ArticleId><ArticleId IdType="pubmed">28346439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LY, Wang JF, Wang LS, Ma SR, Liu YH. Anti-enterovirus 71 agents of natural products. Molecules. 2015;20:16320&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331931</ArticleId><ArticleId IdType="pubmed">26370955</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Chen WC, Jiao Y, Hou JQ, Wu QY, Liu YL, et al. Pulsatilla saponin A, an active molecule from Pulsatilla chinensis, induces cancer cell death and inhibits tumor growth in mouse xenograft models. J Surg Res. 2014;188:387&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24576780</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Ye LG, Guan XQ, Liang XS, Li C, Sun Q, et al. Immunopontentiating and antitumor activities of a polysaccharide from Pulsatilla chinensis (Bunge) Regel. Int J Biol Macromol. 2013;54:225&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23246414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun YX, Liu JC, Yu HT, Gong CJ. Isolation and evaluation of immunological adjuvant activities of saponins from the roots of Pulsatilla chinensis with less adverse reactions. Int Immunopharmacol. 2010;10:584&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20159051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YY, He KW, Wang XM. Role of Chinese herbal medicinal ingredients in secretion of cytokines by PCV2-induced endothelial cells. J Immunotoxicol. 2016;13:141&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25721049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YY, Chen X, Duan HQ, Hu YL, Mu X. Pulsatilla decoction and its active ingredients inhibit secretion of NO, ET-1, TNF-alpha, and IL-1 alpha in LPS-induced rat intestinal microvascular endothelial cells. Cell Biochem Funct. 2009;27:284&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19472295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang NX, Shen WH, Zhang Y, Su ZT, Yang SL, Liu YL, et al. Anti-inflammatory and immune-modulatory properties of anemoside B4 isolated from Pulsatilla chinensis in vivo. Phytomedicine. 2019;64:152934.</Citation><ArticleIdList><ArticleId IdType="pubmed">31454651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XN, Song ZG, Qin BY, Zhang XL, Chen LX, Hu YW, et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antivir Res. 2013;97:264&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu TH, Xu YJ, Li HX, Han D, Zhao HF, Xie SX, et al. Two new triterpenoid saponins from Pulsatilla cernua (Thunb.) Bercht. et Opiz. J Asian Nat Prod Res. 2007;9:705&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17994387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu FQ, Sun XH, Xu XF, Jiang XG. SILAC-based proteomic profiling of the suppression of TGF-&#x3b2;1-induced lung fibroblast-to-myofibroblast differentiation by trehalose. Toxicol Appl Pharmacol. 2020;391:114916.</Citation><ArticleIdList><ArticleId IdType="pubmed">32035996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragan AI, Hargreaves VV, Makeyeva EN, Privalov PL. Mechanisms of activation of interferon regulator factor 3: the role of C-terminal domain phosphorylation in IRF-3 dimerization and DNA binding. Nucleic Acids Res. 2007;35:3525&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1920236</ArticleId><ArticleId IdType="pubmed">17483521</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott J, Hall P, Acuna-Retamar M, Ye C, Wathelet MG, Ebihara H, et al. New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells. PLoS One. 2010;5:e11159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887373</ArticleId><ArticleId IdType="pubmed">20567522</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Lee YP, Hung YT, Lin CH, Chuang JI, Lei HY, et al. Exogenous interleukin-6, interleukin-13, and interferon-&#x3b3; provoke pulmonary abnormality with mild edema in enterovirus 71-infected mice. Respir Res. 2011;12:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223501</ArticleId><ArticleId IdType="pubmed">22054060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Xu WB, Xia JL, Liang ZL, Liu Y, Zhang XF, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RL, Shih SR. Strategies to develop antivirals against enterovirus 71. Virol J. 2013;10:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Peng T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antivir Res. 2013;97:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114103</ArticleId><ArticleId IdType="pubmed">23153834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MJ, Tao L, Xu HX. Chinese herbal medicines as a source of molecules with anti-enterovirus 71 activity. Chin Med. 2016;11:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731985</ArticleId><ArticleId IdType="pubmed">26834824</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh SY, An WG. Systems pharmacological approach of Pulsatillae radix on treating Crohn&#x2019;s disease. Evid Based Complement Altern Med. 2017;2017:4198035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474285</ArticleId><ArticleId IdType="pubmed">28659988</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104278</ArticleId><ArticleId IdType="pubmed">24762827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J Virol. 2012;86:3767&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao S, Guan JM, Chen M, Wang WJ, Li CC, Wang YG, et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J Exp Med. 2018;215:699&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5789414</ArticleId><ArticleId IdType="pubmed">29339449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Li XZ, Li PF, Pan ZY, Ding Y, Zou DH, et al. Enterovirus 71 inhibits cellular type I interferon signaling by inhibiting host RIG-I ubiquitination. Micro Pathog. 2016;100:84&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27633794</ArticleId></ArticleIdList></Reference><Reference><Citation>Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43:247&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">113494</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Yla-Anttila P, Sandalova T, Sun R, Achour A, Masucci MG. 14-3-3 scaffold proteins mediate the inactivation of trim25 and inhibition of the type I interferon response by herpesvirus deconjugases. PLoS Pathog. 2019;15:e1008146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6874091</ArticleId><ArticleId IdType="pubmed">31710640</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CS, Rodgers M, Min CK, Lee JS, Kingeter L, Lee JY, et al. The autophagy regulator Rubicon is a feedback inhibitor of CARD9-mediated host innate immunity. Cell Host Microbe. 2012;11:277&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615900</ArticleId><ArticleId IdType="pubmed">22423967</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghazadeh Y, Papadopoulos V. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21:278&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">26456530</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta A, Siu KW, Ralhan R. 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin Ther Targets. 2012;16:515&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">22512284</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan GC, Yang HY, Shi LB, Sun WM, Sui ML, Zhang RG, et al. Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study. PLoS One. 2014;9:e112676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229228</ArticleId><ArticleId IdType="pubmed">25391156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>